Flori­da judge dis­miss­es Zan­tac can­cer claims against GSK, oth­er phar­mas

GSK can breathe a lit­tle eas­i­er af­ter a Flori­da fed­er­al judge dis­missed thou­sands of claims that Zan­tac and re­lat­ed heart­burn prod­ucts caused can­cer, trig­ger­ing a boost in pre­mar­ket trad­ing on Wednes­day.

Plain­tiffs in the sprawl­ing mul­ti­dis­trict lit­i­ga­tion (MDL) at first at­tempt­ed to link pop­u­lar ran­i­ti­dine heart­burn prod­ucts to 10 types of can­cer, but lat­er with­drew breast, kid­ney, col­orec­tal, prostate and lung. On Tues­day, Judge Robin Rosen­berg tossed the re­main­ing claims in liv­er, blad­der, pan­cre­at­ic, esophageal, and stom­ach can­cers, up­on de­ter­min­ing that the al­le­ga­tions were based on “flawed” and “un­re­li­able” ev­i­dence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER